Cargando…
Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience
We evaluated the clinical impact, in daily clinical practice, of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) therapies in patients with type 2 diabetes. Data from 500 unselected consecutive patients were retrospectively analyzed. Only th...
Autores principales: | Piazzolla, Giuseppina, Vozza, Alfredo, Volpe, Sara, Bergamasco, Alessandro, Triggiani, Vincenzo, Lisco, Giuseppe, Falconieri, Michela, Tortorella, Cosimo, Solfrizzi, Vincenzo, Sabbà, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263895/ https://www.ncbi.nlm.nih.gov/pubmed/35859794 http://dx.doi.org/10.1515/med-2022-0504 |
Ejemplares similares
-
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022) -
When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs
por: Volpe, Sara, et al.
Publicado: (2021) -
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
por: Volpe, Sara, et al.
Publicado: (2023) -
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022) -
Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
por: Piazzolla, Giuseppina, et al.
Publicado: (2019)